Which agent is known to reduce output from a pancreatic or high-output fistula?

Octreotide is a synthetic analogue of somatostatin and is recognized for its ability to reduce gastrointestinal secretions, making it effective in managing high-output pancreatic or enteric fistulas. It works by inhibiting various processes in the gut, including the secretion of hormones and intestinal fluids, which subsequently reduces the volume of output from the fistula.

In conditions involving pancreatic or high-output fistulas, excessive fluid loss can lead to significant complications, such as dehydration and electrolyte imbalances. Octreotide helps control this output, promoting better management of the patient's fluid status and potentially enhancing the healing of the fistula.

While somatostatin can also reduce secretions, octreotide is preferred clinically due to its longer duration of action and more predictable effects, making it the agent of choice in such scenarios. Insulin and glucagon, while important hormones in the regulation of glucose metabolism, do not have roles in reducing secretions from fistulas.